U.S. Markets close in 2 hrs 57 mins

Applied Biosciences Corp. (APPB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 9:39AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2000 - 0.2000
52 Week Range0.0500 - 0.8600
Volume250
Avg. Volume1,682
Market Cap2.82M
Beta (5Y Monthly)-3.71
PE Ratio (TTM)N/A
EPS (TTM)-0.2030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Applied BioSciences Corrects April 24, 2020 Press Release

    Applied BioSciences Corp. (the “Company”; OTCQB: APPB), a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases, hereby corrects its April 24, 2020 press release as follows. In the Press Release, the Company incorrectly stated, “On April 1, 2020, immediately after the supplier of the test kit notified the Company that the FDA had informed it that the test kit was not allowed for home use, the Company supplemented its March 31, 2020 press release to remove reference to home use.” The forgoing sentence should have stated that the Company revised its website (not supplemented the March 31, 2020 press release), and is hereby amended to state, “On April 1, 2020, immediately after the supplier of the test kit notified the Company that the FDA had informed it that the test kit was not allowed for home use, the Company revised its websites at https://healthyhandsanitizer.com/ and https://remedipure.com/ to remove reference to home use.”

  • GlobeNewswire

    Applied BioSciences Terminates Agreement to Offer Test Kits and Amends March 31, 2020 Press Release

    Applied BioSciences Corp. (the “Company”; OTCQB: APPB), a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases, today announced that it terminated its agreement with its supplier for COVID-19 test kits. The Company has not distributed, and will not be distributing, the test kit. Additionally, on March 31, 2020, the Company published a press release tilted, “Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19.”

  • GlobeNewswire

    Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19

    Applied BioSciences Corp. (OTC: APPB) (the " Company"), a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics/ biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases, today announced that, further to its recent March 25th, 2020 press release regarding the Company's diversion of production production capacity to product hand sanitizer, it has begun shipping Coronavirus Test Kits (the "Kits" or the "Tests") in the United States. Using a finger prick, the Kits detect both early markers and late stage markers, IgM and IgG antibodies in a human blood sample.